Keyword: Keytruda

Merck needed a big win in melanoma to help it try to catch up to archrival Bristol-Myers Squibb. And over the weekend, it got one.

Merck has put up some monster Keytruda-chemo combo numbers that'll raise the bar for rivals looking to steal the class crown.

With both Merck and Bristol-Myers Squibb rolling out closely watched data this weekend, one analyst has already tapped Merck as the early winner.

Merck’s Keytruda already has the immuno-oncology lead in non-small cell lung cancer, and it’s making sure it stays that way.

After a previous rejection and a discount offer, Roche's immunotherapy Tecentriq snagged an OK from England's influential cost-effectiveness watchdogs.

Following a big finish in the fourth quarter, Bristol-Myers' CEO took home a 10% pay raise for 2017 to $18.7 million. 

Under a 2003 agreement, Array BioPharma says AstraZeneca needs to pony up $192 million.

Thanks to some new data, Roche has a chance to differentiate itself in the immuno-oncology market for lung cancer. Can it translate into significant sales?

Merck just pulled off a coverage feat that some of its immuno-oncology rivals haven’t so far.

After last year’s successful DTC showdown, #FierceMadness is going back to its roots as a quest to determine the best new drug name.